作者
Andrew N Hoofnagle, Jeffrey R Whiteaker, Steven A Carr, Eric Kuhn, Tao Liu, Sam A Massoni, Stefani N Thomas, R Reid Townsend, Lisa J Zimmerman, Emily Boja, Jing Chen, Daniel L Crimmins, Sherri R Davies, Yuqian Gao, Tara R Hiltke, Karen A Ketchum, Christopher R Kinsinger, Mehdi Mesri, Matthew R Meyer, Wei-Jun Qian, Regine M Schoenherr, Mitchell G Scott, Tujin Shi, Gordon R Whiteley, John A Wrobel, Chaochao Wu, Brad L Ackermann, Ruedi Aebersold, David R Barnidge, David M Bunk, Nigel Clarke, Jordan B Fishman, Russ P Grant, Ulrike Kusebauch, Mark M Kushnir, Mark S Lowenthal, Robert L Moritz, Hendrik Neubert, Scott D Patterson, Alan L Rockwood, John Rogers, Ravinder J Singh, Jennifer E Van Eyk, Steven H Wong, Shucha Zhang, Daniel W Chan, Xian Chen, Matthew J Ellis, Daniel C Liebler, Karin D Rodland, Henry Rodriguez, Richard D Smith, Zhen Zhang, Hui Zhang, Amanda G Paulovich
发表日期
2016/1/1
期刊
Clinical Chemistry
卷号
62
期号
1
页码范围
48-69
出版商
American Association for Clinical Chemistry
简介
BACKGROUND
For many years, basic and clinical researchers have taken advantage of the analytical sensitivity and specificity afforded by mass spectrometry in the measurement of proteins. Clinical laboratories are now beginning to deploy these work flows as well. For assays that use proteolysis to generate peptides for protein quantification and characterization, synthetic stable isotope–labeled internal standard peptides are of central importance. No general recommendations are currently available surrounding the use of peptides in protein mass spectrometric assays.
CONTENT
The Clinical Proteomic Tumor Analysis Consortium of the National Cancer Institute has collaborated with clinical laboratorians, peptide manufacturers, metrologists, representatives of the pharmaceutical industry, and other professionals to develop a consensus set of recommendations for peptide …
学术搜索中的文章
AN Hoofnagle, JR Whiteaker, SA Carr, E Kuhn, T Liu… - Clinical chemistry, 2016